Request Demo

Last update 23 Jan 2025

CIAO3

Last update 23 Jan 2025

Basic Info

Synonyms

CIAO3, Cytosolic Fe-S cluster assembly factor NARFL, cytosolic iron-sulfur assembly component 3

+ [9]

Introduction

Component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into extramitochondrial Fe/S proteins. Seems to negatively regulate the level of HIF1A expression, although this effect could be indirect.

Drugs associated with CIAO3

CN118546244

Patent Mining

Target

CIAO3

Mechanism-

Active Org.

Changchun BCHT Biotechnology Co.

Originator Org.

Changchun BCHT Biotechnology Co.

Active Indication

Respiratory Tract Infections

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CIAO3

100 Translational Medicine associated with CIAO3

0 Patents (Medical) associated with CIAO3

480

Literatures (Medical) associated with CIAO3

31 Dec 2024·Human Vaccines & Immunotherapeutics

Pertactin deficiency of Bordetella pertussis : Insights into epidemiology, and perspectives on surveillance and public health impact

Review

Author: Turriani, Elisa ; Prokić, Ivana ; Guignard, Adrienne P. ; Martini, Helena ; Eeuwijk, Jennifer ; Heininger, Ulrich ; Duchenne, Maurine ; Berlaimont, Valérie

Pertussis resurgence has been documented even in countries with high pediatric vaccine coverage. The proportion of Bordetella pertussis isolates not expressing pertactin (PRN) has increased in several countries where acellular pertussis (aP) vaccines are used. We systematically reviewed published literature up to July 2023 on PRN-negative B. pertussis isolates in MEDLINE and Embase with no geographical limitations, complemented with a gray literature search. An increase in the proportion of PRN-negative isolates was observed in countries where aP vaccines were used, while such isolates seem to be absent in countries using whole-cell pertussis vaccination. We reviewed the data supporting aP vaccine-driven evolution of B. pertussis, explored the effects of PRN deficiency on the clinical presentation of pertussis, summarized the evidence for preserved aP vaccine effectiveness, and proposed actions to further improve assessment of the clinical significance of PRN deficiency and its potential impact on pertussis prevention.

31 Dec 2024·Human Vaccines & Immunotherapeutics

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

Article

Author: Lumley, Jessie ; Chen, Ziqiang ; Costantino, Claudio ; Johnson, David ; Westerholt, Soeren ; Martinon-Torres, Federico ; Lambeth, Courtney ; Guerra, Andrea ; Wilck, Marissa ; Marcek, Tomas

DTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vaccination series is sometimes necessary due to, for example, vaccine availability, health-care provider preference, and/or tender awards. The purpose of this study was to describe the safety, tolerability, and immunogenicity of a booster dose of Vaxelis® in participants who previously received a primary infant series of either DTaP2-HBV-IPV-Hib (Hexyon®) or Vaxelis®. Healthy participants approximately 11-13 months of age who previously received a two-dose primary series of Hexyon® (HHV group) or Vaxelis® (VVV group) all received a Vaxelis® booster dose. Immunogenicity was evaluated by measuring antibody levels to individual vaccine antigens approximately 30 days following booster vaccination. Safety was evaluated as the proportion of participants with adverse events (AEs). The proportions of participants with antibody-specific responses for antigens contained in both Vaxelis® and Hexyon® at 30 days post-toddler-booster vaccination with Vaxelis® were comparable between groups, and higher in the VVV group for Vaxelis® antigens PRN and FIM2/3. The overall proportions of participants with AEs were generally comparable between groups. Following a booster dose of Vaxelis®, immune responses were comparable between groups for all shared antigens, and higher in the VVV group for antigens found only in Vaxelis®. The booster was well tolerated in both groups. These data support the use of Vaxelis® as a booster in mixed HV regimens.

01 Nov 2024·Emerging Infectious Diseases

Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia

Article

Author: Barkoff, Alex-Mikael ; Seme, Katja ; Kastrin, Tamara ; Vitek, Marta Grgič ; Mertsola, Jussi ; He, Qiushui

In Slovenia, primary acellular pertussis vaccines (ACVs) containing pertactin (PRN) were mostly used during 1999-2016; ACVs without PRN were introduced in 2017. Among 123 Bordetella pertussis strains collected during 2002-2020, a total of 48 were PRN-deficient; 44 were collected after 2017. Changes to ACVs could increase PRN-deficient B. pertussis and infections.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CIAO3

Basic Info

Related

Analysis